



Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens

Qian Li^{1,3,5}, Rubén Cebrián^{1,5}, Manuel Montalbán-López^{1,4}, Huan Ren², Weihui Wu² & Oscar P. Kuipers¹  

The development and dissemination of antibiotic-resistant bacterial pathogens is a growing global threat to public health. Novel compounds and/or therapeutic strategies are required to face the challenge posed, in particular, by Gram-negative bacteria. Here we assess the combined effect of potent cell-wall synthesis inhibitors with either natural or synthetic peptides that can act on the outer-membrane. Thus, several linear peptides, either alone or combined with vancomycin or nisin, were tested against selected Gram-negative pathogens, and the best one was improved by further engineering. Finally, peptide D-11 and vancomycin displayed a potent antimicrobial activity at low μM concentrations against a panel of relevant Gram-negative pathogens. This combination was highly active in biological fluids like blood, but was non-hemolytic and non-toxic against cell lines. We conclude that vancomycin and D-11 are safe at >50-fold their MICs. Based on the results obtained, and as a proof of concept for the newly observed synergy, a *Pseudomonas aeruginosa* mouse infection model experiment was also performed, showing a 4 \log_{10} reduction of the pathogen after treatment with the combination. This approach offers a potent alternative strategy to fight (drug-resistant) Gram-negative pathogens in humans and mammals.

¹Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 7, 9747AG Groningen, The Netherlands. ²State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Molecular Microbiology and Technology of the Ministry of Education, Department of Microbiology, College of Life Sciences, Nankai University, 30071 Tianjin, China. ³Present address: State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Collaborative Innovation Center for Green Transformation of Bio-Resources, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, 430062 Wuhan, China. ⁴Present address: Department of Microbiology, Faculty of Sciences, University of Granada, Av. Fuentenueva s/n, 18071 Granada, Spain. ⁵These authors contributed equally: Qian Li, Rubén Cebrián. ✉email: o.p.kuipers@rug.nl

Antimicrobial resistance (AMR) is a natural process enhanced by the widespread use and misuse of antibiotics. The critical increase of AMR poses a major and serious worldwide threat to public health. Following the introduction of lipopeptides in 2003, hardly any new families of antibiotics have been developed, while the existing drugs are rapidly becoming ineffective^{1–4}. Currently, 700,000 deaths per year can be attributed to the spread of antimicrobial resistance and this number is estimated to increase to 10,000,000 by the year 2050⁵. In 2017, the World Health Organization (WHO) published the global priority list, with 12 antibiotic-resistant bacteria for which new antimicrobials or therapeutic strategies are urgently needed⁶. Remarkably, 9 of the 12 “superbugs” listed are Gram-negative pathogens. Their outer-membrane acts as an efficient barrier to prevent various antimicrobials from reaching their targets at the inner membrane and/or the cytoplasm, which complicates the development of efficient treatments against (multidrug-resistant, MDR) bacteria^{7,8}. Passage of the outer-membrane is an essential step in the killing of Gram-negative cells by many antibiotics and antimicrobials. The efficacy of individual antimicrobials can be enhanced by combination with other (either antimicrobial or inactive) permeabilizing compounds^{9,10}.

Cell-wall biosynthesis and maintenance are essential processes in bacteria and their inhibition leads to growth arrestment and death. In fact, diverse groups of successful antibiotics abolish cell-wall biosynthesis as their primary mechanism of action. Lipid II is a key and highly conserved molecule bringing the cell-wall building blocks to the outside of the cellular membrane¹¹. Nisin and vancomycin are potent antimicrobials inhibiting cell-wall biosynthesis by binding to lipid II at the cell membrane using two different binding motifs. They have low micromolar minimal inhibitory concentrations (MICs) but are poorly active on Gram-negative bacteria due to the presence of their outer-membrane^{12–14}. Recently, the replacement of the C terminus of the lantibiotic nisin with short peptide sequences increased the antimicrobial activity 4- to 12-fold against relevant Gram-negative microorganisms¹⁵, showing the outer-membrane permeating potency of these peptides. Thus, we hypothesized that if we could find compounds that can perturb or transiently permeate the

Gram-negative outer-membrane, this would enable vancomycin or nisin to access the periplasm and reach lipid II, resulting in substantial activity against Gram-negative pathogens¹⁶.

In this study, eight, either natural or synthetic, peptides ranging in size between 11 and 23 amino acids, which exert low to modest activity against Gram-negative bacteria, were selected from literature to work as possible Gram-negative outer-membrane-penetrating or -perturbing peptides, thereby exposing lipid II in the inner membrane to either nisin or vancomycin. A first screening was done using nisin or vancomycin as a partner in combination with either peptide. Nine additional variants of the best peptide identified, i.e., L-8, were designed and the best candidate was used to potentiate the activity of the anti-Gram-positive antibiotic vancomycin. Eventually, the D-11 peptide was obtained, which showed very high synergistic activity when combined with vancomycin. We demonstrate its safety with respect to cytotoxicity, hemolysis, and activity in vivo, indicating its high potential in combination with vancomycin as a future therapeutic agent.

Results

Minimal inhibitory concentration (MICs) of peptides alone and in combination with lipid II-targeting antimicrobials.

Vancomycin and nisin were selected because they are potent antimicrobials against Gram-positive bacteria whereas they display low or absent activity against Gram-negative bacteria. Also, they are considered as safe antimicrobials in food preservation (nisin)¹⁷ or in clinical application (vancomycin)¹⁴, and both use the same target, lipid II, to kill bacteria. Eight peptides were selected from literature that displayed low or modest activity against Gram-negative bacteria. Initially, activity tests for vancomycin, nisin and the selected peptides were performed against five clinically relevant Gram-negative pathogens (Table 1). Their MICs ranged from 0.5 μ M to more than 256 μ M in a strain-dependent manner and, as expected, the antimicrobial activity of either vancomycin or nisin was quite low (Table 1).

After this test, the peptides L-1 to L-8 were combined with either vancomycin or nisin and initially tested against *E. coli*

Table 1 Sequences and MIC (μ M) of the different peptides and antimicrobials used in this work. D amino acids are indicated in lowercase.

Name	Sequence	Source	Strains				
			<i>E. coli</i> LMG 15862	<i>K. pneumoniae</i> LMG 20218	<i>P. aeruginosa</i> LMG 6395	<i>A. baumannii</i> LMG 01041	<i>E. aerogenes</i> LMG 02094
L-1	GNNRPVYIPQRPHPRL	62	0.5	5	>64	>64	8
L-2	VDKPPYLP RP RP RI YNR	63	4	8	>64	16	>64
L-3	VDKGSYLPRPTPRPIYNRN-NH ₂	64	3	16	32	8	>32
L-4	RLLFRKIRRLKR	65	64	>256	>128	>128	>256
L-5	RIWVIWRR-NH ₂	66	3	6	3	2	5
L-6	RRLFRRILRWL-NH ₂	67	2	4	3	2	8
L-7	GIGKHVHGKALKGLKGLLKGLEGE	68	6	12	13	2	8
L-8	KRIVQRIKKWLR-NH ₂	69	4	64	16	16	32
L-9	-RIVQRIKKW-R-NH ₂	This work	256	>256	>256	>256	>256
L-10	-RIVQRIKKWL--NH ₂	This work	32	64	16	128	>256
L-11	-RIVQRIKKWLR-NH ₂	This work	12	32	16	>64	128
L-12	-KIVQRIKKWLR-NH ₂	This work	16	32	16	128	256
L-13	-AIVQRIKKWLR-NH ₂	This work	12	24	16	128	128
L-14	-RIRKRIKKWLR-NH ₂	This work	16	>256	16	>256	>256
L-15	-RIKRRIKKWLR-NH ₂	This work	24	>256	32	>256	>256
D-11	rivqrikwlr-NH ₂	This work	4	32	16	8	32
D-11R	rlwkkirqvir-NH ₂	This work	8	32	16	64	32
Vancomycin			64	128	128	32	192
Nisin			12	48	36	6	32

Table 2 Combined activity of L-1 to L-8 peptides and either vancomycin or nisin against five Gram-negative pathogens.

	L-1	L-2	L-3	L-4	L-5	L-6	L-7	L-8
<i>E. coli</i> LMG 15862								
Vancomycin	32	32	32	16	32	16	16	32
Peptide	0.125	2	1.5	16	0.75	1	3	0.25
FICI	0.75	1	1	0.75	0.75	0.75	0.75	0.563
Nisin	1.5	1.5	3	3	0.75	1.5	1.5	1.5
Peptide	0.13	2	1.5	8	0.75	0.5	1.5	1
FICI	0.375	0.625	0.75	0.375	0.313	0.375	0.375	0.375
<i>P. aeruginosa</i> LMG 6395								
Vancomycin		128	128	32		128		64
Peptide		32	1.5	1.5		6.5		8
FICI		1.25	1.5	0.75		1.5		1
Nisin		4.5	2.25	4.5		4.5		4.5
Peptide		64	0.75	0.75		3.25		1
FICI		0.625	0.313	0.375		0.375		0.188
<i>K. pneumoniae</i> LMG 20218								
Vancomycin		64	64	32		64		8
Peptide		0.625	3	1		3		8
FICI		0.625	1	0.5		0.75		0.188
Nisin		6	6	3		3		0.75
Peptide		1.25	1.5	0.5		0.75		4
FICI		0.375	0.375	0.188		0.125		0.078
<i>A. baumannii</i> LMG 01041								
Vancomycin		16	16	8		16		4
Peptide		16	0.5	0.5		0.25		4
FICI		0.625	0.75	0.5		0.625		0.375
Nisin		1.5	0.75	0.75		0.75		0.19
Peptide		64	0.5	0.5		0.5		1
FICI		0.546	0.375	0.375		0.375		0.094
<i>E. aerogenes</i> LMG 02094								
Vancomycin		192	192	64		192		48
Peptide		8	5	2		4		4
FICI		2	2	0.583		1.5		0.375
Nisin		4	4	2		4		2
Peptide		4	1.25	1		1		8
FICI		0.625	0.375	0.188		0.25		0.313

In the table are listed the MICs (μM) for vancomycin, nisin and the peptides for the best combination, as well as the FICI calculation. For an explanation of FICI and how it is calculated see the "Methods" section. Synergistic combinations are labeled in bold. For the FICI calculations twice the highest concentration tested was used in the cases where the MIC was not reached. Individual MICs are listed in Table 1.

LMG 15862. Interestingly, all the peptides tested displayed some synergistic effect with nisin against *E. coli*, with the exception of L-2 and L-3 that only showed an additive effect (Table 2). However, in the combination with vancomycin, the effect was mainly additive and L-8, with a Fractional Inhibitory Concentration Index (FICI) of 0.563, showed the best synergy (Table 2). Considering the best reduction in the MIC of either vancomycin or nisin, the peptides L-1, L-5, L-6, L-7 and L-8 were selected for further characterization of the synergistic effect against a panel of 4 other Gram-negative medically relevant bacteria (Table 2).

The combination of the selected peptides with nisin was synergistic in all the cases against all the bacteria tested with the exception of the L-1 peptide (Table 2). The combination of L-8 with either vancomycin or nisin displayed the best synergism against almost all of the five Gram-negative pathogens, while the combined effect of the other peptides with vancomycin was modest and, in general, additive, and strain-specific (Table 2). The peptide L-6, which was also (less) synergistic in some combinations, was discarded because it showed rather high hemolytic activity in the previous studies¹⁸. Notably, L-8 had very low hemolytic activity¹⁹, which made it the best candidate for

further studies. Based on these results, peptide L-8 was selected for a round of further modifications.

L-8 peptide improvement. In order to increase the combined effect, seven variants of L-8 were designed. Several parameters such as peptide truncation, role of arginine/lysine, amphiphilicity, and hydrophobicity were explored²⁰. Based on this, three shorter variants were designed to increase the drug potential of the peptide and then, for the best one, another four variants were designed (Table 1 and Supplementary Fig. 1). In general, none of the newly designed peptides systematically outperformed L-8 (Table 1). However, in combination with either vancomycin or nisin an astonishing improvement of the synergy was observed for the peptide L-11 (Table 3). This peptide, being just one amino acid smaller than the original L-8, was better in synergy with vancomycin in all the cases against all the bacteria as well as in the combination with nisin, with the exception of *Pseudomonas*, where the FICI value was the same (Table 3). The reduction in the MIC of vancomycin in combination with L-11 ranged between 8-fold reduction for *Pseudomonas* and 32-fold for *Klebsiella*. The synergistic effect varied in a strain-specific manner with the other designed peptides (Table 3). Considering several parameters as

Table 3 Combined activity of L-peptides and either vancomycin or nisin against five Gram-negative pathogens.

	L-8	L-9	L-10	L-11	L-12	L-13	L-14	L-15
<i>E. coli</i> LMG 15862								
Vancomycin	32	8	8	4	4	4	4	4
Peptide	0.25	16	4	1.5	2	3	2	3
FICI	0.563	0.188	0.25	0.188	0.188	0.313	0.188	0.188
Nisin	1.5	6	3	1.5	1.5	1.5	3	3
Peptide	1	64	2	1.5	2	1.5	2	3
FICI	0.375	0.75	0.313	0.25	0.25	0.25	0.375	0.375
<i>P. aeruginosa</i> LMG 6395								
Vancomycin	64	ND	16	16	16	4	4	16
Peptide	8	ND	2	2	2	8	8	8
FICI	1	ND	0.25	0.25	0.25	0.531	0.531	0.5
Nisin	4.5	ND	4.5	4.5	4.5	4.5	2.25	9
Peptide	1	ND	4	1	4	8	4	8
FICI	0.188	ND	0.375	0.188	0.375	0.625	0.313	0.5
<i>K. pneumoniae</i> LMG 20218								
Vancomycin	8	ND	16	4	16	16	ND	ND
Peptide	8	ND	16	2	8	3	ND	ND
FICI	0.188	ND	0.375	0.094	0.375	0.25	ND	ND
Nisin	0.75	ND	3	0.75	0.75	1.5	ND	ND
Peptide	4	ND	1	1	2	3	ND	ND
FICI	0.078	ND	0.078	0.047	0.078	0.156	ND	ND
<i>A. baumannii</i> LMG 01041								
Vancomycin	4	ND	1	2	4	4	ND	ND
Peptide	4	ND	16	1	4	8	ND	ND
FICI	0.375	ND	0.125	0.070	0.156	0.188	ND	ND
Nisin	0.19	ND	0.375	0.19	0.375	0.375	ND	ND
Peptide	1	ND	16	4	16	32	ND	ND
FICI	0.094	ND	0.188	0.070	0.188	0.313	ND	ND
<i>E. aerogenes</i> LMG 02094								
Vancomycin	48	ND	ND	12	12	12	ND	ND
Peptide	4	ND	ND	8	16	16	ND	ND
FICI	0.375	ND	ND	0.125	0.125	0.188	ND	ND
Nisin	2	ND	ND	4	4	4	ND	ND
Peptide	8	ND	ND	8	1	8	ND	ND
FICI	0.313	ND	ND	0.188	0.128	0.188	ND	ND

In this table, the MICs (μM) of vancomycin, nisin, and the peptides for the best combination, as well as the FICI calculation, are listed. Peptides with a better synergism coefficient than L-8 are displayed in bold. For the FICI calculations, twice the highest concentration tested was used in the cases where the MIC was not reached. Individual MICs are listed in Table 1. ND no synergy determined.




Fig. 1 Plasma stability for the peptides L-11, D-11 and D-11R. a Antimicrobial activity of the peptides L-11, D-11, and D-11R against *K. pneumoniae* LMG 20218 after their incubation in PBS. **b** Antimicrobial activity of the peptides L-11, D-11, and D-11R after their incubation in human plasma.

size, activity alone and activity in the combinations, peptide L-11 was selected for further (pre-clinical) characterization.

Plasma stability. In view of the clinical potential, plasma stability is a desirable quality of newly designed antimicrobials^{21,22}. So, before further analysis, the stability of L-11 in plasma was analyzed. The peptide was incubated in PBS (Fig. 1a) and plasma (Fig. 1b), and the reduction in the antimicrobial activity was tested by a spot-on-lawn assay against *K. pneumoniae*. The peptide L-11 was not very stable in plasma, being almost completely degraded within the first 3 h (Fig. 1b). In order to increase the stability, the peptide was synthesized with only D-amino acids

(D-11) making it resistant against peptidases and proteases²³. Moreover, reversed peptides (with a reversal of the peptide sequence) have been reported to be interesting in peptidomimetics and can display good activity^{18,24}. Thus, both variants were synthesized and assayed (D-11 and D-11R). As we can see in Fig. 1b, both D-11, as well as its reversed peptide D-11R, were completely resistant to degradation in plasma.

Antimicrobial activity and synergy of the newly designed peptides. The introduction of D-amino acids or the change in the order of the amino acids may abolish a (putative) receptor interaction, thus allowing to establish whether or not a specific

(proteinaceous) receptor is playing a role. For this reason, and to determine whether the changes affected the previously observed activity, the new variants were tested alone and in synergy with vancomycin against pathogenic multiresistant bacteria, including clinical isolates (Table 1). The impact of D-amino acid replacement in L-11 entailed a drastic improvement against *E. aerogenes* and *A. baumannii* (4 and >8-fold MIC reduction, respectively, for the peptide alone), although no important changes against the rest of the panel was observed. The reversed D-peptide was in general either equally or 2- to 8-fold less active than the D-peptide against the whole panel (Table 1). D-11 and D-11R showed, just as L-11, a strong synergistic effect in all the combinations with either vancomycin or nisin (Supplementary Table 1). Nevertheless, the combinations of D-11 and either vancomycin or nisin showed slightly less synergism than the L-11 peptide with a FICI value ranging between 0.078 and 0.25 but a similar reduction in the MIC value for vancomycin or nisin, so these values still indicate a very strong in vitro synergy (Supplementary Table 1). In general, the combination with nisin was more effective and yielded the lowest FICI values. Notably, the D-peptides exhibited an enhanced activity against Gram-negative pathogens, when compared to the L-counterpart. The reversed peptide sequence did not largely change the activities of the peptides except against *A. baumannii*. These results suggest that the selected L-11, D-11, and D-11R do not interact with a specific proteinaceous receptor, which would require stereospecific interactions.

Since D-amino acids confer higher resistance against proteolysis, are more stable in serum and blood, and because the activity in synergy was not greatly altered, D-11 was selected for further tests in combination with vancomycin against clinical isolated MDR bacteria. Synergy with vancomycin may constitute an interesting therapeutic alternative, since it is smaller than nisin and -in contrast to nisin- is currently used as an antibiotic in clinical therapy. As before (Table 1), the vancomycin activity alone against these strains was low, while the combined activity of vancomycin and D-11 was strain-specific and synergistic (Table 4). The most sensitive strains to vancomycin in combination with D-11 were *E. coli* and *A. baumannii*, and the best synergistic effect was obtained for the strains *E. coli* ATCC BAA-2452, *K. pneumoniae* ATCC BAA-2524, *K. pneumoniae* B1945, and *A. baumannii* ATCC BAA-1605 (Table 4).

The bactericidal effect of vancomycin, D-11, and the combinations thereof were determined against five Gram-negative strains. The final concentration of the compounds used

was 10-fold the MIC of each compound measured either individually (Table 1) or in combination (Table 3). Unlike the positive controls (untreated cells), no colonies of any of the five Gram-negative pathogens could grow after treatment incubation for 3 h (Supplementary Fig. 2). There was no growth recovery after exposure to vancomycin, D-11, and the combinations thereof, so both the compounds alone and the combinations thereof are bactericidal.

Mechanistic aspects of the synergistic action. According to our hypothesis, the peptide is perturbing the outer-membrane, enabling vancomycin to access the periplasm, thus reaching its target lipid II. To test whether the outer-membrane is the main target of D-11, the antimicrobial activity of D-11 and vancomycin was tested against 5 different Gram-positive bacteria, which do not have an outer-membrane (Supplementary Table 2). D-11 MIC was above 64 μM in all cases (with the exception of *E. faecium* that was 10.4 μM). In addition, no synergy in the combination with vancomycin was observed. This data suggests that the activity of D-11 is due to its action on the outer-membrane.

The role of LPS and Mg^{2+} in the activity. To prove the role of the outer-membrane structure in the synergistic killing mechanism, we tested the influence of LPS and magnesium ions on the activity of vancomycin and D-11 against the Gram-negative bacteria panel. Both vancomycin and D-11 (especially this one) exhibited a reduced antimicrobial effect against all the tested pathogens when the cells were grown in the presence of exogenous LPS or Mg^{2+} (Supplementary Table 3). When LPS was in the medium, the MICs of vancomycin against Gram-negative pathogens increased 2-fold, except against *A. baumannii*. Remarkably, 2- to more than 16-fold D-11 was needed to inhibit the growth of Gram-negative pathogens in the presence of LPS and this reduction was even more drastic in the presence of an outer-membrane-stabilizing agent as Mg^{2+} (Supplementary Table 3).

The effect of exogenous LPS and Mg^{2+} was also analyzed in the synergistic combination. As depicted in Fig. 2a, LPS considerably suppressed the ability of D-11 to potentiate vancomycin against Gram-negative pathogens. As an example, 2 μM vancomycin and 1 μM D-11 can inhibit the growth of *K. pneumoniae* without the addition of LPS. However, at least 32 μM vancomycin and 16 μM D-11 were needed after the addition of excess LPS. When 21 mM Mg^{2+} was added to the growth medium for the checkerboard

Table 4 Combined activity of D-11 and vancomycin (μM) against an extended panel of MDR Gram-negative clinical isolated pathogens.

Strains	MIC _A	MIC _B	MIC _{AB}	MIC _{AC}	FICI
<i>E. coli</i> ATCC 25922	>88.32	5.36	5.52	1.6	0.329
<i>E. coli</i> ATCC BAA-2452	>88.32	5.36	2.76	0.80	0.164
<i>E. coli</i> B1927	88.32	2.68	5.52	1.6	0.659
<i>K. pneumoniae</i> ATCC700603	>88.32	>85.68	11.04	10.71	0.081
<i>K. pneumoniae</i> ATCC BAA-2524	>88.32	>85.68	11.04	3.21	0.081
<i>K. pneumoniae</i> B1945	>88.32	21.41	11.04	3.21	0.212
<i>P. aeruginosa</i> ATCC 27853	>88.32	42.84	11.04	10.71	0.312
<i>P. aeruginosa</i> ATCC BAA-2108	>88.32	>85.68	44.15	42.84	0.499
<i>P. aeruginosa</i> B1954	88.32	85.68	44.15	42.84	1
<i>P. aeruginosa</i> PA14	88.32	128	32	8	0.422
<i>A. baumannii</i> ATCC 17978	88.32	10.71	5.52	1.61	0.22
<i>A. baumannii</i> ATCC BAA-1605	44.16	10.71	2.76	0.80	0.137
<i>A. baumannii</i> B2026	22.08	10.71	2.76	2.68	0.376

MIC_A is the MIC of vancomycin alone; MIC_B corresponds to the MIC of D-11 when used alone; MIC_{AB} is the MIC of vancomycin in combination with the peptide at the MIC_{AC} concentration. MIC_{AC} is the MIC of D-11 when used with the MIC_{AB} concentration of vancomycin. Synergistic combinations are labeled in bold. For the FICI calculations, twice the highest concentration tested was used in the cases where the MIC was not reached.




Fig. 2 Effect of LPS in the D-11/vancomycin synergism and outer-membrane permeabilization assay. **a** Checkerboard broth microdilution assay diagram showing the effect of LPS and Mg^{2+} in the D-11/vancomycin synergistic relation. Dark region represents higher cell density. **b** Dose-dependent outer-membrane permeabilization by D-11 against different Gram-negative bacteria. Polymyxin B was used as a positive control and vancomycin as negative.

broth microdilution assays, D-11 was not able to potentiate vancomycin against any of the five Gram-negative pathogens, which grew at the tested concentrations (Fig. 2a). This is consistent with the results when vancomycin and D-11 were tested alone in the presence of LPS and Mg^{2+} (Supplementary Table 3) and suggests that the outer-membrane is the main target for D-11.

D-11 is perturbing the outer-membrane. The activity of D-11 on the outer-membrane was tested measuring NPN (1-N-phenyl-naphthylamine) uptake. The outer-membrane was permeabilized by D-11 in a dose-dependent manner in all the Gram-negative bacteria tested (Fig. 2b). As expected, no permeabilization was observed for vancomycin, while polymyxin B (positive control) exerted a strong activity. These results suggest that the D-11 peptide can disrupt the integrity of the outer-membrane of these Gram-negative pathogens via association with LPS, thereby enhancing the permeability of the outer-membrane. This helps to sensitize the Gram-negative pathogens to antibiotics as vancomycin that, otherwise, are restricted to act against Gram-positive bacteria.

Cell toxicity and hemolytic activity of vancomycin and D-11. In order to prove the safety of vancomycin, D-11, and their

combinations, toxicity tests against human cell lines and hRBCs were performed. As we can see in Fig. 3a, vancomycin and D-11 did not affect the viability of human HEK-293 cells, neither alone nor in combination at all the concentrations tested (up to 88 μ M). After that, fresh hRBCs were used for the hemolytic tests. Vancomycin and D-11 did not cause any hemolysis of hRBCs even at concentrations as high as 500 and 600 μ M, respectively (Supplementary Table 4).

When combined, vancomycin and D-11 did not cause hemolysis at the highest concentration tested. The cell selectivity of the peptides is identified as the therapeutic index (TI)^{19,25}, which is a parameter related to the toxicity and the effect of drugs (Supplementary Table 4). A higher TI is preferable for an antimicrobial to be considered safe. The TI of vancomycin and D-11 was 11.4 and 39.03, respectively. The TI of D-11 is ~3.4-fold higher than that of vancomycin and this highlights the safety of peptide D-11.

Antimicrobial activity in blood. The stability of D-11 was previously confirmed in plasma. However, whole blood is a complex medium in which the synergistic interaction between vancomycin and D-11 can be affected by many additional parameters and factors. An in vitro bacteremia infection model was developed by the infection of whole blood with 10^8 colony forming units




Fig. 3 Toxicity and activity ex vivo/in vivo of D-11 with or without vancomycin. **a** Effect on the cell viability for vancomycin (vanco.), D-11, and their combination against HEK-293 cells. **b** Ex vivo bacteremia model for vancomycin, D-11, and their combinations. 10 μ L of serial decimal dilutions of each one of the combinations of vancomycin (16, 8, 4, and 2 μ M) with/without D-11 (4 μ M) tested in blood were dropped. **c** In vivo efficacy of vancomycin and D-11 alone and its combination (comb.) against *P. aeruginosa* PA14. Saline is the negative control.

(CFU)/mL of *K. pneumoniae* LMG 20218. 10 μ L of each one of the tubes were collected at different times, they were decimal serially diluted and plated to quantify the evolution of the infection in blood. As we can see in Fig. 3b, in the presence of vancomycin and D-11, the number of colonies observed was always lower than that of the controls (vancomycin alone or D-11 alone) and during the different time points, with the exception of the combination of 2 μ M vancomycin and 4 μ M D-11. After 6 h of incubation, 10¹² CFU/mL were counted for the negative controls as well as for the treatment with 8, 4, and 2 μ M vancomycin (10¹⁰ CFU/mL for the treatment with 16 μ M vancomycin). In the D-11 treated blood, 10¹² CFU/mL were counted for the negative control (just D-11), 10¹⁰ CFU/mL for the combination with 2 μ M vancomycin, 10⁶ CFU/mL for the combination with 4 and 8 μ M vancomycin and 10⁴ CFU/mL for the combination with 16 μ M vancomycin.

A proof of concept. The in vivo efficacy. Encouraged by the in vitro results and the potential of dose-sparing drug combinations in therapy, we tested the efficacy of D-11 in combination with vancomycin in a murine abscess model of *P. aeruginosa* PA14 (Fig. 3c). Here, we observed that the combination of D-11 (10 mg/kg) and vancomycin (3 mg/kg) was highly efficacious, causing a more than 4 log₁₀ reduction of CFU in the abscess (Fig. 3c), whereas after treatment with the individual compounds the cell count was similar to that of the saline negative control.

Discussion

Combined antibiotic therapy has been pivotal in the treatment of bacterial infections such as tuberculosis and can prevent resistance appearance^{26,27}. In addition, (antimicrobial) peptides constitute a yet unused alternative in antimicrobial therapy in spite of their potential⁵. Here, we attempted to expand the spectrum of lipid II binding antimicrobials such as vancomycin and nisin, so that they can be used against (resistant) Gram-negative bacteria by a synergy strategy using natural or synthetic peptides.

Compounds with different targets on bacterial cells can display very good synergistic effects against pathogens, thereby allowing dose-sparing and reducing their individual toxicity, which has an enormous potential in therapy^{10,28,29}. In this work, several peptides from different origins were selected and tested for synergy together with two classes of lipid II binding antimicrobials (vancomycin and nisin). Additionally, engineering of the best hits provided a variant, L-11, with great potential to extend vancomycin's spectrum against (MDR) Gram-negative pathogens. Synergies of vancomycin with other antimicrobials are well documented when targeting Gram-positive bacteria^{30–32}, as well as its synergy in combination with outer-membrane perturbing (or not³³) antibiotics as colistins^{34,35}. However, these combinations are still under study because of the relatively high toxicity observed³⁶. There is not much information available on the synergy of vancomycin and peptides against Gram-negative bacteria and, if there are data, the observed effect is additive and the concentrations of vancomycin needed in these combinations are outside of the clinically relevant range^{9,37,38}.

Plasma stability is a key factor during the clinical development of a compound and peptides that have a short half-life are unlikely to reach clinical application^{21,22,39}. It is known that D-amino acids are protected against the action of peptidases^{23,40}, thus, two total D-amino acids forms were synthesized: the direct one (D-11) and the reversed one (D-11R). These two variants were completely stable in plasma and largely retain the activity against an (MDR) Gram-negative bacteria panel. The fact that both the D- and L-amino acids-containing peptides were similarly active indicates that the activity does not rely on binding to a specific receptor and therefore its ability to interact with the outer-membrane was tested.

The most variable part in the outer-membrane is the LPS. To date, more than 200 different LPS forms have been described just for *E. coli* (ECODAB database)⁴¹. LPS is a polyanionic molecule with numerous phosphate groups that generates repulsive forces (due to accumulation of the negative charges) that are screened and bridged by the divalent cations (Mg^{2+} and Ca^{2+}) which are known to be crucial for the integrity of the outer-membrane⁴². Our data suggest that this peptide is prone to interact with LPS, causing outer-membrane perturbation, which potentiates the activity of Gram-positive-specific antimicrobials (e.g., vancomycin and nisin) against Gram-negative pathogens, including antibiotic-resistant strains. The presence of Mg^{2+} could influence the MIC, not only because of an increased outer-membrane stability, but also because of its electrostatic competition with D-11 ($pI = 12.3$). In fact, in the presence of Mg^{2+} , a larger peptide concentration is needed to reach a coverage high enough on the membrane surface to permeabilize it⁴³. Additionally, NPN permeabilization in the presence of D-11 indicates that the outer-membrane is altered, in a similar way as polymyxin B does. This kind of activity has been previously reported for small α -helical and/or cationic peptides^{44–46}. Alteration of the overall structure of the outer-membrane is, in principle, difficult to achieve through simple point mutations but would require a deep change in the Gram-negative bacterial physiology. Thus, a compound acting on this essential component constitutes an important advance in anti-Gram-negative antibiotic therapy.

Another important point addressed in this study is the absence of toxicity against HEK-293 cells and also the absence of hemolytic activity even at high concentrations. This is especially important since D-11 is a cationic peptide, which are usually not toxic against cells lines but they are often hemolytic and poorly stable in plasma⁴⁷.

Finally, the combination was tested in a bacteremia model in blood. The activity of exogenous antimicrobial peptides in blood has been referred previously against both Gram-negative and positive bacteria^{48,49}, but never in synergy tests. The combination of D-11 and vancomycin was highly active in blood, controlling the infection by *K. pneumoniae* in the conditions tested. Importantly, the concentration of vancomycin used in this study falls within the dose range of vancomycin currently applied in humans in the case of Gram-positive bacterial infections (MDR organisms may require daily doses up to 60 mg/kg, equivalent to $\sim 40 \mu M$, www.drugs.com). The in vitro experiments suggest that (combinations of) vancomycin and D-11 are safe at therapeutic concentrations and that the antimicrobial activity of the synergy takes place efficiently in human fluids like blood. These data encouraged us for an in vivo experiment, since the application of antimicrobial peptides often fails due to their low activity in the presence of plasma⁵⁰. As a proof of concept, mice were infected with *P. aeruginosa*, and after the treatments, we observed an important reduction in the CFU in the mice treated with the combination, whereas the single components did not show this effect. Similar results have been observed for the combination of the antiparasitic drug pentamidine (inactive against bacteria) with

some antibiotics⁵¹. Pentamidine behaves as a powerful adjuvant sensitizing Gram-negative bacteria to typical anti-Gram-positive antibiotics or even to polymyxins in resistant organisms. Remarkably, the poor combined effect with vancomycin suggests a different mechanism of action that could be even complementary in the treatment of Gram-negative pathogens⁵¹.

In summary, the combinations here described constitute a therapeutic approach to deal with (MDR) Gram-negative pathogens. The efficacy of vancomycin and D-11 further indicates their high potential for clinical use. In spite of the relatively low activity of D-11 alone, the astonishing synergism of D-11 with vancomycin and nisin raises the possibility of D-11 to be registered as an adjuvant instead of an antimicrobial itself. The D-11 peptide fulfills the requirement to be considered as a good drug candidate: high efficacy (in synergy), low toxicity to eukaryotic cells, blood stability, high proteolytic stability, and low cost²⁰. So far all the results indicate that D-11 has the potential to become an important drug to combat the emerging resistance problem that the world is facing⁵². Further development is currently ongoing to collect all the pre-clinical data to enable first in human studies.

Methods

Bacterial strains, cell lines, and growth conditions. The bacterial strains used in this study are listed in Supplementary Table 5. Gram-negative bacteria were routinely grown in LB medium (Formedium, Norfolk, UK) and shaking (200 rpm) at 37 °C, while Gram-positive strains were grown statically in M-17 broth (BD Difco, New Jersey, US) plus 0.5% glucose (GM-17) at 37 °C with the exception of *Streptococcus* strains that were cultured in C + Y medium as described by Aprianto et al.⁵³. For solid media agar at 1.5 % final concentration was added.

The human embryonic kidney cell line HEK-293 was obtained from the American type culture collection (ATCC) and cultured in Dulbecco's modified Eagle's medium (DMEM) growth medium supplemented with 1% non-essential amino acids (NEAA) and 10% fetal bovine serum (FBS) (Sigma-Aldrich, Ontario, Canada).

Peptides, antimicrobials, reagents, and chemicals. The peptides used in this work were synthesized by Pepsican (Lelystad, The Netherlands) (Table 1). For the purification and quantification of nisin, commercial nisin was suspended in 0.05% acetic acid and further purified by HPLC (Agilent 1260 Infinity LC) equipped with a semi-preparative C12 column (Phenomenex 250 × 10 mm). The fractions were collected, tested for activity against *L. lactis*, and analyzed with MALDI-TOF. The active, fully dehydrated and pure fractions were freeze-dried. The freeze-dried nisin was weighted and dissolved with 0.05% acetic acid⁵⁴. Vancomycin, polymyxin B, $MgCl_2$, lipopolysaccharide (LPS) from *Escherichia coli* O55:B5, HEPES buffer, and chloral hydrate were purchased from Sigma-Aldrich. Sodium phosphate tablets, DMEM, non-essential amino acids (NEAA) were purchased from ThermoFisher Scientific (Waltham, Massachusetts, USA). CellTiter-glo reagent was purchased from Promega (Leiden, the Netherlands). Human plasma EDTA K2 Mixed-Gender was purchased from Sera Laboratories International, Ltd (West Sussex, United Kingdom).

MIC determination and synergy test. MIC tests were performed in triplicate by liquid growth inhibition microdilution assays in sterile polypropylene microtiter plates according to the Clinical and Laboratory Standards Institute (CLSI) guideline for bacteria that grow aerobically⁵⁵. Briefly, the indicator strains were first streaked on the appropriate agar plate, and then single colonies were picked and incubated overnight in liquid broth. The final inoculum of bacteria was 5×10^5 CFU/mL prepared in CAMHB (cationic adjusted Mueller–Hinton broth, Sigma-Aldrich) or CAMHB plus 5% of lysed horse blood (TCS Biosciences, Buckingham, UK) in the case of *S. pneumoniae*. The antimicrobials were 2-fold serially diluted and 50 μL diluted bacterial suspension was added to each well to make the final volume 100 μL . The microtiter plates and the count plates were incubated at 37 °C for 16–20 h without shaking. Growth inhibition was assessed by measuring the OD₆₀₀ using a microplate reader (Tecan Infinity F200). The lowest concentration of the antimicrobials that inhibits visible growth of the indicator strain is identified as the MIC value.

For the synergy test, standard checkerboard broth microdilution assays were conducted to test the synergistic effect of combined antimicrobials using the same condition as before^{51,56}. Vancomycin or nisin (compound A) was loaded 2-fold serially diluted at the X axis, while peptides (compound B) were 2-fold serially diluted at the Y axis. The initial concentration of both peptides was their individual MIC. 50 μL fresh bacterial suspension prepared as above was added to the wells already containing the antimicrobial compound mixture to achieve 100 μL final volume per well.

The fractional inhibitory concentration (FIC) indices⁵⁷ were calculated using the formula $FICI = FICa + FICb = MICa/MICa + MICb/MICb$, to determine whether the combination is additive, synergistic or antagonistic^{51,57}. The MICa and MICb is the MIC of compound A or B alone, respectively. MICac is the MIC of compound A in combination with compound B and MICbc is the MIC of compound B when it was combined with compound A. The FIC corresponds to the MIC of a compound in combination with the other compound, divided by the MIC of the compound alone. FICa is FIC of compound A while FICb is FIC of compound B. The FICI was interpreted according to EUCAST⁵⁸ as follows: synergistic, $FICI \leq 0.5$; additive, $0.5 < FICI \leq 1$; indifferent, $1 < FICI < 2$; antagonistic, $FICI \geq 2$.

For the bactericidal effect testing, the bacteria were inoculated in CAMHB medium at 5×10^5 CFU/mL and incubated at 37 °C for 3 h in the presence of vancomycin, D-11 alone or their combinations at $10 \times$ MIC concentrations (Tables 1 and 3). After that, 50 μ L of a 10^3 -fold diluted sample were plated on LB agar⁵⁹.

Plasma stability test. For plasma stability, the peptides were lyophilized and resuspended in plasma or PBS (as a control) at a final concentration of 3.2 mM. After that, the peptides were incubated with shaking (200 rpm) during 6 h at 37 °C. At time 1, 3, and 6 h, 10 μ L samples were tested against *K. pneumoniae* LMG 20218 by a spot-on-lawn test. Reduction in the size of the halo was related to the degradation of the peptide. The test was performed in triplicate.

Mechanism of action of selected peptides

Effect of LPS and Mg^{2+} on the activity and synergy of selected peptides. The effect of LPS (the major component of the outer-membrane) and Mg^{2+} (divalent cations are involved in an increase of the stability of the outer-membrane and they are essential for its integrity) on the activity of peptide D-11 alone and/or in combination with vancomycin was tested. For this, 21 mM of $MgCl_2$ and 1.0 mg/mL of LPS purified from *E. coli* O55:B5 (Sigma-Aldrich) were added to the CAMHB medium during the MIC and synergistic tests. The condition for the tests and the analysis of the plates were performed as described above for the MIC tests.

Outer-membrane permeability test. The integrity of the outer-membranes was analyzed measuring the 1-N-phenyl-naphthylamine (NPN) uptake after the treatment with the peptide. The outer-membrane acts as a permeability barrier that excludes hydrophobic compounds as NPN. If the outer-membrane is altered, the dye can enter reaching the phospholipid layer which results in a prominent fluorescence⁶⁰. Briefly, the peptides and/or antibiotics were placed in a 96-well plate at $2 \times$ the desired final concentration in HEPES buffer plus glucose (GHEPES) (5 mM HEPES, 5 mM glucose). Meantime, the Gram-negative bacteria were grown in LB until an OD_{600} of 1. After that, they were washed twice in GHEPES buffer and 2-fold diluted in the same buffer. NPN was dissolved in acetone and added to the cells at 30 μ M final concentration, and after that, the bacteria were distributed in the 96 wells plates previously prepared with the antimicrobials at a final OD_{600} of ~ 0.25 . Immediately the fluorescence for the dye was measured at an excitation/emission range of 350/420 nm every 10 min during 1 h. Polymyxin B was used as a positive control and non-treated cells as negative. All the tests were performed in triplicate.

Hemolytic activity and cytotoxicity. Cytotoxicity and the hemolytic activity of peptide D-11 alone as well as in combination with vancomycin were tested by the company Fidelta Ltd (Zagreb, Croatia) and by Wuhan Elabscience Biotechnology Co., Ltd (Wuhan, China). Hemolytic activity was determined with fresh human red blood cells (hRBCs)²⁸. The hRBCs were centrifuged (1000 \times g, 5 min) and the supernatant was discarded. The pellets were washed three times with PBS and diluted in PBS to make the cell stock solution with a cell density of 2×10^8 cells/mL. The hRBCs suspensions were incubated with vancomycin, the peptide D-11 and their combinations at various concentrations, as indicated. 1% Triton X-100 and PBS were used as controls. The cells were incubated at 37 °C for 1 h and centrifuged at 2000 rpm for 5 min. The supernatant was transferred to a new 96-well plate and hemolysis was monitored by measuring the absorbance at 450 nm (OD_{450}). Hemolysis levels were calculated as percentage. % hemolysis = $100 \times (A_s - A_0) / (A_t - A_0)$, where A_s , A_0 , and A_t are the absorbance of the hRBCs suspension in PBS with antimicrobial agents (A_s), without antimicrobial agents (A_0), and with 1% Triton X-100 (A_t). Based on these data, other parameters, such as the HC50 (concentration that causes 50% hemolysis of hRBCs), the MHC (minimal hemolytic concentration that caused 10% hemolysis of hRBCs), and the TI (therapeutic index) were calculated. For the TI calculation ($TI = MHC/GM$), other factors as the GM (geometric mean of MIC value of all the Gram-negative strains tested) were calculated.

A human embryonic kidney cell line HEK-293 was used to assess the cell viability⁶¹. 96-well plates were seeded with HEK-293 cells at a concentration of 3×10^5 cells/well in 100 μ L of DMEM growth medium supplemented with 1% NEAA and 10% FBS. Border wells were filled with 100 μ L of sterile PBS. Vancomycin and peptide D-11 were added to the cells the next day at various concentrations. ATP levels were measured by adding 50 μ L of CellTiter-Glo reagent (Promega, Madison, US) to each well, and luminescence was measured with a SpectraMax i3 microplate reader after 5 minutes of incubation. The potential

effect of the tested compounds on cell viability was determined by comparing the signal obtained in the presence of different concentrations of the compounds with those obtained in the control wells. All these tests were performed in triplicate.

Antimicrobial activity in blood. Briefly, blood from healthy donors was obtained from Sanquin (certified Dutch organization responsible for meeting the need in healthcare for blood and blood products, <https://www.sanquin.nl/>) and infected with 10^8 CFU/mL of *K. pneumoniae* LMG 20218. After that, the infected blood was split in two, and one of the tubes was inoculated with 4 μ M of the peptide D-11, and the blood was distributed at 0.5 mL in 2 mL Eppendorf tubes. Vancomycin was added at 16, 8, 4, and 2 μ M in the tubes that were incubated at 37 °C for 6 h with gentle shaking. At 1, 2, 4, and 6 h 100 μ L samples were taken from each one of the tubes and decimal serially diluted in PBS. Drops of 10 μ L of each one of the dilutions were spotted on LB agar medium to follow the development of the infection. The experiment was performed in triplicate. Non-infected blood, infected blood, and blood plus peptide were used as a control.

In vivo antimicrobial activity test. As a proof of concept, an in vivo test for the efficacy of the synergy was performed. An overnight *P. aeruginosa* PA14 culture was inoculated into fresh LB medium (100-fold dilution) and grown until an OD_{600} of 1.0. The culture was washed twice and resuspended in 0.9% NaCl to 10^8 CFU/mL. Four groups of five 6-week-old female BALB/c mice were used. They were anesthetized with 7.5% chloral hydrate by intraperitoneal injection, and then subcutaneously injected with 50 μ L of the bacterial suspension at the dorsum of the mice, giving a total infection bacterial number of $\sim 5 \times 10^6$ CFU per mouse. One hour post-infection, 50 μ L of 0.9% NaCl (control group), vancomycin (3 mg/kg), the peptide D-11 (10 mg/kg) and a combination of vancomycin and D-11 at the previous concentrations, respectively, were injected into the infection area. After 24 h, the mice were sacrificed and the abscesses were excised to count the CFU. The bacterial loads were determined by serial dilution and plating. All animal experiments complied with the US and Chinese national guidelines for the use of animals in research. The protocol was approved by the Animal Care and Use Committee of the College of Life Sciences, Nankai University (permission number NK-04-2012). All procedures involving animals were performed after animals were anesthetized. The experimental results were analyzed with the GraphPad Prism software.

Statistic and reproducibility. All experiments were performed in replicates as indicated.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data that support the findings of this study are available from the corresponding author on request. Raw data used for Figs. 2 and 3 are shown in Supplementary Data 1.

Received: 14 May 2020; Accepted: 11 November 2020;

Published online: 04 January 2021

References

- Gill, E. E., Franco, O. L. & Hancock, R. E. W. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. *Chem. Biol. Drug Des.* **85**, 56–78 (2015).
- Fischbach, M. A. & Walsh, C. T. Antibiotics for emerging pathogens. *Science* **325**, 1089–1093 (2009).
- Kristiansson, E. et al. Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. *PLoS ONE* **6**, e17038 (2011).
- Piddock, L. J. V. Reflecting on the final report of the O'Neill review on antimicrobial resistance. *Lancet Infect. Dis.* **16**, 767–768 (2016).
- O'Neill, J. *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance* (Review on Antimicrobial Resistance, 2016).
- WHO. *Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics* (WHO, 2017).
- Santajit, S. & Indrawattana, N. Mechanisms of antimicrobial assistance in ESCAPE pathogens. *BioMed Res. Int.* **2016**, 2475067 (2016).
- Helander, I. M., von Wright, A. & Mattila-Sandholm, T.-M. Potential of lactic acid bacteria and novel antimicrobials against Gram-negative bacteria. *Trends Food Sci. Technol.* **8**, 146–150 (1997).
- Vaara, M. Agents that increase the permeability of the outer membrane. *Microbiol. Rev.* **56**, 395–411 (1992).
- Field, D., Seisling, N., Cotter, P. D., Ross, R. P. & Hill, C. Synergistic nisin-polymyxin combinations for the control of *Pseudomonas* biofilm formation. *Front. Microbiol.* **7**, 1713 (2016).

11. Breukink, E. & de Kruijff, B. Lipid II as a target for antibiotics. *Nat. Rev. Drug Discov.* **5**, 321–332 (2006).
12. Loll, P. J. & Axelsen, P. H. The structural biology of molecular recognition by vancomycin. *Annu. Rev. Biophys. Biomol. Struct.* **29**, 265–289 (2000).
13. Iancu, C. et al. Comparison of the potency of the lipid II targeting antimicrobials nisin, lactacin 3147 and vancomycin against Gram-positive bacteria. *Probiotics Antimicrob. Proteins* **4**, 108–115 (2012).
14. WHO. 19th WHO Model List of Essential Medicines. https://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.
15. Li, Q., Montalban-Lopez, M. & Kuipers, O. P. Increasing the antimicrobial activity of nisin-based lantibiotics against Gram-negative pathogens. *Appl. Environ. Microbiol.* **84**, e00052–18 (2018).
16. Cavera, V. L., Arthur, T. D., Kashtanov, D. & Chikindas, M. L. Bacteriocins and their position in the next wave of conventional antibiotics. *Int. J. Antimicrob. Agents* **46**, 494–501 (2015).
17. Hansen, J. N. Nisin as a model food preservative. *Crit. Rev. Food Sci. Nutr.* **34**, 69–93 (1994).
18. Atzori, A., Baker, A. E., Chiu, M., Bryce, R. A. & Bonnet, P. Effect of sequence and stereochemistry reversal on p53 peptide mimicry. *PLoS ONE* **8**, e68723 (2013).
19. Chen, Y. et al. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. *J. Biol. Chem.* **280**, 12316–12329 (2005).
20. Li, J. et al. Membrane active antimicrobial peptides: translating mechanistic insights to design. *Front. Neurosci.* **11**, 73 (2017).
21. Zhang, C. et al. Design, synthesis and evaluation of new ligustrazine derivatives as potential plasma-stable neuroprotective agents. *MedChemComm* **8**, 652–656 (2017).
22. Böttger, R., Hoffmann, R. & Knappe, D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. *PLoS ONE* **12**, e0178943 (2017).
23. Hong, S. Y., Oh, J. E. & Lee, K. H. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. *Biochem. Pharmacol.* **58**, 1775–1780 (1999).
24. Vadukul, D. M., Gbajumo, O., Marshall, K. E. & Serpell, L. C. Amyloidogenicity and toxicity of the reverse and scrambled variants of amyloid- β 1–42. *FEBS Lett.* **591**, 822–830 (2017).
25. Kim, E. Y., Rajasekaran, G. & Shin, S. Y. LL-37-derived short antimicrobial peptide KR-12-a5 and its d-amino acid substituted analogs with cell selectivity, anti-biofilm activity, synergistic effect with conventional antibiotics, and anti-inflammatory activity. *Eur. J. Med. Chem.* **136**, 428–441 (2017).
26. Brown, E. D. & Wright, G. D. Antibacterial drug discovery in the resistance era. *Nature* **529**, 336–343 (2016).
27. Kerantzas, C. A. & Jacobs, W. R. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. *mBio* **8**, e01586–16 (2017).
28. Naghmouchi, K. et al. Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. *Antimicrob. Agents Chemother.* **57**, 2719–2725 (2013).
29. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. *Nat. Chem. Biol.* **7**, 348–350 (2011).
30. Hornak, J. P., Anjum, S. & Reynoso, D. Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant *Staphylococcus aureus* bacteremia after monotherapy failure. *Ther. Adv. Infect. Dis.* **6**, 2049936119886504 (2019).
31. Lewis, P. O., Sevinsky, R. E., Patel, P. D., Krolkowski, M. R. & Cluck, D. B. Vancomycin plus nafcillin salvage for the treatment of persistent methicillin-resistant *Staphylococcus aureus* bacteremia following daptomycin failure: a case report and literature review. *Ther. Adv. Infect. Dis.* **6**, 2049936118797404 (2019).
32. Wu, T., Meyer, K., Harrington, A. T., Danziger, L. H. & Wenzler, E. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci. *J. Antimicrob. Chemother.* **74**, 1300–1305 (2019).
33. Zhou, A. et al. Synergistic interactions of vancomycin with different antibiotics against *Escherichia coli*: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type *E. coli*. *Antimicrob. Agents Chemother.* **59**, 276–281 (2015).
34. Oliva, A. et al. In vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant *Acinetobacter baumannii*. *Mol. Basel Switz.* **24**, 886 (2019).
35. Sertcelik, A., Baran, I., Akin, E., Mumcuoglu, I. & Bodur, H. Synergistic activities of colistin combinations with meropenem, sulbactam, minocycline, disodium fosfomicin, or vancomycin against different clones of carbapenem-resistant *Acinetobacter baumannii* strains. *Microb. Drug Resist. Larchmt. N.* **26**, 429–433 (2019).
36. Claeys, K. C., Fiorvento, A. D. & Rybak, M. J. A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrug-resistant *Acinetobacter baumannii*. *Infect. Dis. Ther.* **3**, 69–81 (2014).
37. Wu, X. et al. Synergistic effects of antimicrobial peptide DP7 combined with antibiotics against multidrug-resistant bacteria. *Drug Des. Dev. Ther.* **11**, 939–946 (2017).
38. Mohammed, I., Said, D. G., Nubile, M., Mastropasqua, L. & Dua, H. S. Cathelicidin-derived synthetic peptide improves therapeutic potential of vancomycin against *Pseudomonas aeruginosa*. *Front. Microbiol.* **10**, 2190 (2019).
39. Lewis, A. L. & Richard, J. Challenges in the delivery of peptide drugs: an industry perspective. *Ther. Deliv.* **6**, 149–163 (2015).
40. Güell, I. et al. Improvement of the efficacy of linear undecapeptides against plant-pathogenic bacteria by incorporation of D-amino acids. *Appl. Environ. Microbiol.* **77**, 2667–2675 (2011).
41. Rojas-Macias, M. A., Stähle, J., Lütke, T. & Widmalm, G. Development of the ECODAB into a relational database for *Escherichia coli* O-antigens and other bacterial polysaccharides. *Glycobiology* **25**, 341–347 (2015).
42. Clifton, L. A. et al. Effect of divalent cation removal on the structure of Gram-negative bacterial outer membrane models. *Langmuir ACS J. Surf. Colloids* **31**, 404–412 (2015).
43. Lam, N. H., Ma, Z. & Ha, B.-Y. Electrostatic modification of the lipopolysaccharide layer: competing effects of divalent cations and polycationic or polyanionic molecules. *Soft Matter* **10**, 7528–7544 (2014).
44. Piers, K. L., Brown, M. H. & Hancock, R. E. Improvement of outer membrane-permeabilizing and lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification. *Antimicrob. Agents Chemother.* **38**, 2311–2316 (1994).
45. Wang, J. et al. High specific selectivity and membrane-active mechanism of the synthetic centrosymmetric α -helical peptides with Gly-Gly pairs. *Sci. Rep.* **5**, 15963 (2015).
46. Nam, B.-H. et al. Antimicrobial activity of peptides derived from olive flounder lipopolysaccharide binding protein/bactericidal permeability-increasing protein (LBP/BPI). *Mar. Drugs* **12**, 5240–5257 (2014).
47. Gautam, A. et al. Hemolytic: a database of experimentally determined hemolytic and non-hemolytic peptides. *Nucleic Acids Res.* **42**, D444–D449 (2014).
48. Yeaman, M. R., Gank, K. D., Bayer, A. S. & Brass, E. P. Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. *Antimicrob. Agents Chemother.* **46**, 3883–3891 (2002).
49. Cebrián, R. et al. Preclinical studies of toxicity and safety of the AS-48 bacteriocin. *J. Adv. Res.* **20**, 129–139 (2019).
50. Marr, A. K., Gooderham, W. J. & Hancock, R. E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. *Curr. Opin. Pharmacol.* **6**, 468–472 (2006).
51. Stokes, J. M. et al. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. *Nat. Microbiol.* **2**, 17028 (2017).
52. Li, Q. & Kuipers, O. P. Antimicrobial peptides and admixtures thereof showing antimicrobial activity against Gram-negative pathogens. Patent no. WO2018231058 (2018).
53. Aprianto, R., Slager, J., Holsappel, S. & Veening, J.-W. High-resolution analysis of the pneumococcal transcriptome under a wide range of infection-relevant conditions. *Nucleic Acids Res.* **46**, 9990–10006 (2018).
54. Zhou, L., van Heel, A. J. & Kuipers, O. P. The length of a lantibiotic hinge region has profound influence on antimicrobial activity and host specificity. *Front. Microbiol.* **6**, 11 (2015).
55. CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: M07-A10; Approved Standard* (Committee for Clinical Laboratory Standards, 2015).
56. Lehar, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. *Nat. Biotechnol.* **27**, 659–666 (2009).
57. Odds, F. C. Synergy, antagonism, and what the checkerboard puts between them. *J. Antimicrob. Chemother.* **52**, 1 (2003).
58. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). EUCAST Definitive Document E.Def 1.2, May 2000: terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. *Clin. Microbiol. Infect. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.* **6**, 503–508 (2000).
59. Naghmouchi, K., Belguesmia, Y., Baah, J., Teather, R. & Drider, D. Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of *Listeria monocytogenes* and *Escherichia coli*. *Res. Microbiol.* **162**, 99–107 (2011).
60. Helander, I. M. & Mattila-Sandholm, T. Fluorometric assessment of gram-negative bacterial permeabilization. *J. Appl. Microbiol.* **88**, 213–219 (2000).
61. Pernel, L., Kotnik, M., Prezelj, A. & Urleb, U. Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits. *J. Biomol. Screen.* **14**, 142–150 (2009).

62. Czihal, P. et al. Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens. *ACS Chem. Biol.* **7**, 1281–1291 (2012).
63. Knappe, D. et al. Oncocin (VDKPPYLPRPRPPRIYNR-NH₂): a novel antibacterial peptide optimized against Gram-negative human pathogens. *J. Med. Chem.* **53**, 5240–5247 (2010).
64. Cudic, M. et al. Development of novel antibacterial peptides that kill resistant isolates. *Peptides* **23**, 2071–2083 (2002).
65. Rao, S. S., Mohan, K. V. K. & Atreya, C. D. A peptide derived from phage display library exhibits antibacterial activity against *E. coli* and *Pseudomonas aeruginosa*. *PLoS ONE* **8**, e56081 (2013).
66. Spindler, E. C., Hale, J. D. F., Giddings, T. H., Hancock, R. E. W. & Gill, R. T. Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c. *Antimicrob. Agents Chemother.* **55**, 1706–1716 (2011).
67. Torcato, I. M. et al. Design and characterization of novel antimicrobial peptides, R-BP100 and RW-BP100, with activity against Gram-negative and Gram-positive bacteria. *Biochim. Biophys. Acta* **1828**, 944–955 (2013).
68. Ilić, N. et al. Selective antimicrobial activity and mode of action of adeptantins, glycine-rich peptide antibiotics based on anuran antimicrobial peptide sequences. *Biochim. Biophys. Acta* **1828**, 1004–1012 (2013).
69. Jacob, B., Park, I.-S., Bang, J.-K. & Shin, S. Y. Short KR-12 analogs designed from human cathelicidin LL-37 possessing both antimicrobial and antiendotoxic activities without mammalian cell toxicity. *J. Pept. Sci. Publ. Eur. Pept. Soc.* **19**, 700–707 (2013).

Acknowledgements

Qian Li was supported by the Chinese Scholarship Council (NO 201306770012). Manuel Montalbán-López was supported by a grant of the EU FP7 Programme SynPeptide. Rubén Cebrián was supported by the NWO-NACTAR program. We thank Prof. Gert Moll for his help with the revision of this manuscript.

Author contributions

O.P.K. and M.M.-L. conceived and designed the project; Q.L. and R.C. conducted the experiment related to the peptide selection and design, MIC test analysis, synergism combinations, mechanism of action elucidation, toxicity data analysis, and blood test;

W.W. and H.R. designed and performed all the mice related experiment and the related writing. Q.L., M.M.-L., R.C.C., and O.P.K. wrote and reviewed the paper. All the authors approved the final paper.

Competing interests

The authors declare the following competing interests: Part of the results presented in this work have been patented⁵². Each of the authors do not have any interests exceeding \$10,000 or 5% equity in a company that has any relation to this work.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s42003-020-01511-1>.

Correspondence and requests for materials should be addressed to O.P.K.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021